Recombinant interferon gamma in hairy cell leukemia, multiple myeloma, and Waldenstrom's macroglobulinemia. Am J Hematol 1988 Sep;29(1):1-4
Date
09/01/1988Pubmed ID
3140655DOI
10.1002/ajh.2830290102Scopus ID
2-s2.0-0023788106 (requires institutional sign-in at Scopus site) 56 CitationsAbstract
Fifteen patients with multiple myeloma, five with hairy cell leukemia, and five with Waldenstrom's macroglobulinemia were treated with recombinant interferon gamma (rINF-gamma) to determine the antitumor activity of this agent. The rIFN-gamma was administered by daily intramuscular injection at doses ranging from 0.125 to 0.5 mg/m2. No responses were observed in patients with multiple myeloma, although in one patient the disease has remained stable for over 16 months. Minimal improvement in some hematologic indexes were observed in three of five patients with hairy cell leukemia. One partial remission and one minor response were documented in two of the five patients with Waldenstrom's macroglobulinemia. In five patients, an increase in normal serum immunoglobulins was observed. These results suggest that there is only minimal activity of rIFN-gamma as a single agent in neoplasms of B-cell origin.
Author List
Quesada JR, Alexanian R, Kurzrock R, Barlogie B, Saks S, Gutterman JUAuthor
Razelle Kurzrock MD Center Associate Director, Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdultAged
Asthenia
Blood Cell Count
Drug Evaluation
Fatigue
Female
Hematologic Diseases
Humans
Interferon-gamma
Leukemia, Hairy Cell
Male
Middle Aged
Multiple Myeloma
Recombinant Proteins
Waldenstrom Macroglobulinemia
